AbCellera Biologics Inc (NASDAQ:ABCL) has a beta value of -61.25% and has seen 4.78 shares traded in the last trading session. The company, currently valued at $1.02B, closed the last trade at $3.47 per share which meant it lost -$4.86 on the day or 3.41% during that session. The ABCL stock price is -6.05% off its 52-week high price of $3.68 and 45.53% above the 52-week low of $1.89.
The consensus among analysts is that AbCellera Biologics Inc (ABCL) is Buy stock at the moment, with a recommendation rating of 76.76. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 9 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Sporting 3.41% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ABCL stock price touched $3.47 or saw a rise of 2.25%. Year-to-date, AbCellera Biologics Inc shares have moved 11.44%, while the 5-day performance has seen it change 8.25%. Over the past 30 days, the shares of AbCellera Biologics Inc (NASDAQ:ABCL) have changed 63.16%.
Wall Street analysts have a consensus price target for the stock at $23.5, which means that the shares’ value could jump 85.23% from current levels. The projected low price target is $5.0 while the price target rests at a high of $34.0. In that case, then, we find that the current price level is -879.83% off the targeted high while a plunge would see the stock gain -44.09% from current levels.
AbCellera Biologics Inc (ABCL) estimates and forecasts
The company’s shares have gained 19.23% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was – -107.74% over the past 5 years. Earnings growth for 2025 is a modest -10.77% while over the next 5 years, the company’s earnings are expected to increase by 0.83%.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
The top two institutional holders are BAKER BROS. ADVISORS LP with over 27.53 million shares worth more than $81.48 million. As of 2024-06-30, BAKER BROS. ADVISORS LP held 9.3556% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 21.91 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.86 million and represent 7.4472% of shares outstanding.
